TCA
IOVA icon

Transcend Capital Advisors’s Iovance Biotherapeutics IOVA Stock Holding History

Transcend Capital Advisors’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-21,900
Closed -$206K – 608
2024
Q3 		$206K Sell
21,900
-600
-3% -$5.68K 0.01% 577
2024
Q2 		$180K Buy
+22,500
New +$241K 0.01% 568
2021
Q2 		– Sell
-6,830
Closed -$216K – 362
2021
Q1 		$216K Sell
6,830
-2,250
-25% -$93.3K 0.03% 371
2020
Q4 		$421K Buy
9,080
+236
+3% +$9.37K 0.06% 253
2020
Q3 		$291K Buy
+8,844
New +$271K 0.05% 210

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return

Transcend Capital Advisors's IOVA Position: Q4 2024 in Review

Transcend Capital Advisors sold out of Iovance Biotherapeutics (IOVA) in Q4 2024, closing a stake of 21,900 shares — an estimated $206K sold.

Transcend Capital Advisors first reported a position in IOVA in Q3 2020 and held it in 5 quarters. The position peaked at $421K in Q4 2020. 301 funds tracked by Wall St. Rank hold IOVA as of Q4 2024.

  • Transcend Capital Advisors reported no remaining Iovance Biotherapeutics position as of Q4 2024 after selling out during the quarter.
  • Transcend Capital Advisors sold 21,900 Iovance Biotherapeutics shares in Q4 2024, an estimated $206K.
  • Transcend Capital Advisors first reported a position in Iovance Biotherapeutics in Q3 2020 and held it in 5 quarters.
  • Transcend Capital Advisors's Iovance Biotherapeutics position peaked at $421K in Q4 2020.
  • 301 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2024.

Based on Transcend Capital Advisors's 13F filing for Q4 2024, filed 3 Feb 2025.